IMMUNITYBIO, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
IMMUNITYBIO, INC. (IBRX) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$15.51 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-05-07
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$15.51M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$13.64M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$10.13M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$14.95M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$48.78M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$38.59M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$25.30M.
- IMMUNITYBIO, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$5.42M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | -$15.51M 10-Q · filed 2018-05-07 | -$29.15M derived: sum of 2 quarters · filed 2018-05-07 | -$39.28M derived: sum of 3 quarters · filed 2018-05-07 | -$54.23M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-12-31 | -$13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$23.77M derived: sum of 2 quarters · filed 2018-03-12 | -$38.72M derived: sum of 3 quarters · filed 2018-03-12 | -$48.78M 10-K · filed 2018-03-12 | ||
| 2017-09-30 | -$10.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$25.08M derived: sum of 2 quarters · filed 2017-11-07 | -$35.14M 10-Q · filed 2017-11-07 | -$45.89M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-06-30 | -$14.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$25.01M 10-Q · filed 2017-08-07 | -$35.76M derived: sum of 3 quarters · filed 2018-05-07 | -$46.44M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-03-31 | -$10.06M 10-Q · filed 2018-05-07 | -$20.81M derived: sum of 2 quarters · filed 2018-05-07 | -$31.49M derived: sum of 3 quarters · filed 2018-05-07 | -$39.79M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2016-12-31 | -$10.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$21.44M derived: sum of 2 quarters · filed 2018-03-12 | -$29.74M derived: sum of 3 quarters · filed 2018-03-12 | -$38.59M 10-K · filed 2018-03-12 | ||
| 2016-09-30 | -$10.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$18.98M derived: sum of 2 quarters · filed 2017-11-07 | -$27.84M 10-Q · filed 2017-11-07 | -$38.78M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-06-30 | -$8.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$17.16M 10-Q · filed 2017-08-07 | -$28.10M derived: sum of 3 quarters · filed 2018-03-12 | -$32.30M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-03-31 | -$8.86M 10-Q · filed 2017-05-08 | -$19.80M derived: sum of 2 quarters · filed 2018-03-12 | -$24.00M derived: sum of 3 quarters · filed 2018-03-12 | -$26.79M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2015-12-31 | -$10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$15.14M derived: sum of 2 quarters · filed 2018-03-12 | -$17.93M derived: sum of 3 quarters · filed 2018-03-12 | -$25.30M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | -$4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$6.99M derived: sum of 2 quarters · filed 2016-11-10 | -$14.36M 10-Q · filed 2016-11-10 | -$14.22M 10-Q · filed 2015-11-12 | -$16.93M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-06-30 | -$2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$10.16M 10-Q · filed 2016-08-15 | -$10.04M 10-Q · filed 2015-09-10 | -$12.74M derived: sum of 3 quarters · filed 2017-03-15 | -$13.49M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$7.37M 10-Q · filed 2016-05-16 | -$9.95M derived: sum of 2 quarters · filed 2017-03-15 | -$10.70M derived: sum of 3 quarters · filed 2017-03-15 | -$12.75M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$2.57M derived: 10-K 12 month − 10-K 9 month · filed 2017-03-15 | -$3.33M derived: sum of 2 quarters · filed 2017-03-15 | -$5.38M derived: sum of 3 quarters · filed 2017-03-15 | -$5.42M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$753.00K derived: 10-K 9 month − 10-K 6 month · filed 2016-03-30 | -$2.81M derived: sum of 2 quarters · filed 2016-03-30 | -$2.84M 10-K · filed 2016-03-30 | -$2.80M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$2.05M derived: 10-K 6 month − 10-K 3 month · filed 2016-03-30 | -$2.09M 10-K · filed 2016-03-30 | -$2.09M 10-Q · filed 2015-09-10 | |||
| 2014-03-31 | -$38.00K 10-K · filed 2016-03-30 | |||||
| 2013-12-31 | -$668.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |